Mer­ck flesh­es out Keytru­da win in first-line cer­vi­cal can­cer, adding more fire­pow­er to its ear­ly can­cer push

4 years ago
R&D

Mer­ck­'s Keytru­da un­corks full da­ta on lat­est ad­ju­vant win — this time in melanoma — adding bricks to ear­ly can­cer ...

4 years ago
R&D

Lat­est news: It’s a no on uni­ver­sal boost­ers; Pa­tient death stuns gene ther­a­py field; In­side Tril­li­um’s $2.3B ...

4 years ago
Weekly

Chaot­ic ad­comm sees Pfiz­er/BioN­Tech boost­ers re­ject­ed for gen­er­al pop­u­la­tion, but rec­om­mend­ed for old­er and high-risk ...

4 years ago
Coronavirus

Skin tu­mors in mice force Pro­tag­o­nist to halt lead pro­gram, crush­ing stock

4 years ago
FDA+

Chi­nese biotech Ever­est signs $550M+ li­cens­ing deal for BTK in­hibitors on heels of Covid-19 pact

4 years ago
Deals
China

Philip Mor­ris gets share­hold­er back­ing in Vec­tura saga; Tarve­da strikes ex­clu­sive li­cens­ing agree­ment with Sci­Clone

4 years ago
News Briefing

EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

4 years ago
R&D

As­traZeneca touts Imfinzi im­munother­a­py com­bos for lung can­cer in push to dri­ve PD-L1 drug up­take

4 years ago
R&D

Eu­ro­pean study finds that Gilead­'s Covid-19 an­tivi­ral remde­sivir shows no clin­i­cal ben­e­fit

4 years ago
Coronavirus

Gri­fols drops $1B on Ger­man hold­ing com­pa­ny in con­tin­ued plas­ma push

4 years ago
Deals

The biggest ques­tions fac­ing gene ther­a­py, the XLMTM com­mu­ni­ty, and Astel­las af­ter fourth pa­tient death

4 years ago
Cell/Gene Tx
FDA+

Covid-19 roundup: FDA re­veals boost­er ad­comm ques­tion; Eli Lil­ly's an­ti­body cock­tail cleared for pre­ven­tion

4 years ago
Coronavirus

A Pfiz­er part­ner wel­comes ex-ADC Ther­a­peu­tics CMO Jay Fein­gold to the team; Amid tough sled­ding, Im­muno­vant choos­es ...

4 years ago
Peer Review

AGC un­veils Ger­man ex­pan­sion plans as gene and cell ther­a­py man­u­fac­tur­ing com­pe­ti­tion heats up

4 years ago
Manufacturing

DNA play­er Touch­light dou­bles fundrais­ing this year with lat­est round of pri­vate back­ers on board

4 years ago
Manufacturing

Emer­gent gets a chance to re­deem it­self in mR­NA vac­cine deal with Prov­i­dence Ther­a­peu­tics

4 years ago
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Kenya will add man­u­fac­tur­ing plant, up vac­ci­na­tion sites; South Ko­rea left wait­ing on ...

4 years ago
Coronavirus
Manufacturing

NeuEx­cell strikes deal with Fu­ji­film for stroke gene ther­a­py; J&J ex­pands in Ire­land

4 years ago
Manufacturing

Re­call re­port: Chil­dren's au­to-im­mune dis­ease drug con­t­a­m­i­nat­ed with mold and yeast

4 years ago
Manufacturing

FDA ac­cepts In­tel­li­a's IND for CRISPR and TCR-T cell ther­a­py; San­té clos­es Fund IV at $260M

4 years ago
News Briefing

No­vo Nordisk Foun­da­tion tees up $47.5M to ex­plore the dri­vers of ge­net­ic dis­ease with the Broad In­sti­tute

4 years ago
Deals

Chi­nese CAR-T play­er books a megaround to dri­ve bustling cell ther­a­py port­fo­lio through the clin­ic

4 years ago
Financing

Gilead keeps push­ing trove of Trodelvy da­ta as it seeks to be­come new stan­dard of care in TNBC

4 years ago
R&D
First page Previous page 648649650651652653654 Next page Last page
A service from the Financial Times